News – Page 1087 – Endpoints News

Shkreli out, Cuban in: Twitter proves essential for biotech rebel Ethan Perlstein

8 years ago

Agios spotlights promising data for IDH1 drug, putting it on the path to FDA submission

8 years ago

FDA panel votes yes on Indivior’s opioid addiction drug

8 years ago

AstraZeneca inks a cardio drug development pact with mRNA specialist Moderna

8 years ago

#ASH17: Novartis’ 6-month Kymriah data in DLBCL sets up a head-to-head fight with Gilead

8 years ago

#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status

8 years ago

#ASH17: Bluebird touts early signs that its new-and-improved sickle cell gene therapy is working

8 years ago

California upstart Xyphos wants to tackle CAR-T's big problems

8 years ago

AstraZeneca’s asthma drug tralokinumab goes 0 for 3 in PhIII as 2 more trials flop

8 years ago

Frazier boosts next pure-play biotech fund to $419M, readies new bets for a practiced strategy

8 years ago

Greek health minister takes issue with Roche's withdrawal of cancer medicine due to mandatory, retroactive discount

8 years ago

Neos considering offers after rejecting PDL’s $300M bid: Reuters

8 years ago

AstraZeneca gets an early green light on BTK blockbuster hopeful Calquence

8 years ago

Expanding its preclinical attack on Duchenne MD, Sarepta grabs a license for Duke's CRISPR tech

8 years ago

Regeneron, Sanofi rack up a PhIII asthma win for dupilumab; Verastem preps FDA app for duvelisib

8 years ago

Stemline wraps positive pivotal trial for its controversial lead cancer drug, clearing a path to the FDA

8 years ago

Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on

8 years ago

PhIII dealmaking frenzy in i/o continues as AstraZeneca follows PACIFIC with a new Incyte IDO1 combo

8 years ago

Bristol-Myers, J&J sink cash into a new $95M European biotech fund

8 years ago

Grail CSO Vikram Bajaj jumps to VC firm Foresite, takes lead on personalized meds

8 years ago

Sanofi Genzyme retreats from its Parkinson’s deal with gene therapy upstart Voyager, part of an $845M pact

8 years ago

Can tiny Mustang Bio compete on the CAR-T front with giants like Novartis and Gilead? Manny Litchman aims to find out

8 years ago

Bloodied Celgene posts promising ozanimod PhIII MS data, but is it really a $6 billion drug?

8 years ago

Insiders: The top 20 rare disease specialists spotlight key biotech trends behind the boom

8 years ago

First page Previous page 1084 1085 108610871088 1089 1090 Next page Last page